Clinical Trial

Exploratory Study of MSLN-CAR T Cells Secreting PD1/CTLA-4 Nanoantibody for the Treatment of Advanced Solid Tumors

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 8, 2024 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologous mesothelin (MSLN)-targeted chimeric antigen receptor (MSLN-CAR) T cells secreting PD-1 and CTLA-4 nanobodies (αPD1/CTLA-4-MSLN-CAR T cells) in patients with solid tumors.
Trial Details
NCT Number NCT06248697
Lead Sponsor Shanghai Cell Therapy Group Co.,Ltd
Conditions Solid Tumor
Enrollment 16 participants
Start Date 2023-01-01
Primary Completion 2026-07-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-02-08